Metformin and Inflammation: Its Potential Beyond Glucose-lowering Effect

Author(s): Yoshifumi Saisho .

Journal Name: Endocrine, Metabolic & Immune Disorders - Drug Targets

Volume 15 , Issue 3 , 2015

Become EABM
Become Reviewer

Abstract:

Metformin is an oral hypoglycemic agent which is most widely used as first-line therapy for type 2 diabetes. Metformin improves hyperglycemia by suppressing hepatic glucose production and increasing glucose uptake in muscle. Metformin also has been shown to reduce cardiovascular events in randomized controlled trials; however, the underlying mechanism remains to be established. Recent preclinical and clinical studies have suggested that metformin not only improves chronic inflammation through the improvement of metabolic parameters such as hyperglycemia, insulin resistance and atherogenic dyslipidemia, but also has a direct anti-inflammatory action. Studies have suggested that metformin suppresses inflammatory response by inhibition of nuclear factor κB (NFκB) via AMP-activated protein kinase (AMPK)-dependent and independent pathways. This review summarizes the basic and clinical evidence of the anti-inflammatory action of metformin and discusses its clinical implication.

Keywords: AMPK, anti-inflammatory effect, biguanide, NFκB, type 2 diabetes.

Rights & PermissionsPrintExport Cite as

Article Details

VOLUME: 15
ISSUE: 3
Year: 2015
Page: [196 - 205]
Pages: 10
DOI: 10.2174/1871530315666150316124019

Article Metrics

PDF: 270